AstraZeneca Shares Are Trading Higher. The European Union Approved the Company's Fasenra as an Add-on Treatment as an Add-on Treatment for Adult Patients With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis.
AstraZeneca Shares Are Trading Higher. The European Union Approved the Company's Fasenra as an Add-on Treatment as an Add-on Treatment for Adult Patients With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis.
阿斯利康股價上漲。歐盟批准該公司的Fasenra作爲成人複發性或難治性嗜酸性粒細胞性肉芽腫伴多發性血管炎的附加治療。
AstraZeneca Shares Are Trading Higher. The European Union Approved the Company's Fasenra as an Add-on Treatment as an Add-on Treatment for Adult Patients With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis.
阿斯利康股價上漲。歐盟批准該公司的Fasenra作爲成人複發性或難治性嗜酸性粒細胞性肉芽腫伴多發性血管炎的附加治療。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間